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The integration of genomic and epigenomic data is an increasingly popular approach for studying the complex
mechanisms driving cancer development. We have developed a method for evaluating both methylation and copy
number from high-density DNA methylation arrays. Comparing copy number data from Infinium HumanMethylation450
BeadChips and SNP arrays, we demonstrate that Infinium arrays detect copy number alterations with the sensitivity of
SNP platforms. These results show that high-density methylation arrays provide a robust and economic platform for
detecting copy number and methylation changes in a single experiment. Our method is available in the ChAMP
Bioconductor package: http://www.bioconductor.org/packages/2.13/bioc/html/ChAMP.html.Background
Copy number alterations (CNAs) have been implicated
in the development and progression of many human
malignancies, including prostate, bladder and breast can-
cer [1-4]. Since first described in the late 1990s, many
platforms have been developed for assessing alterations
in genomic copy number at an ever increasing resolution
[5-9]. The latest version of copy number variation arrays
can interrogate over one million loci, and have the abil-
ity to detect genomic alterations ranging from approxi-
mately 4 kb to over 2 Mb [10-13]; they are, however,
limited in the size of small alterations detectable, due to
the distance between loci interrogated (Table 1). As a re-
sult, many small/micro-deletions encompassing single
genes may not be detectable [9].
In parallel, arrays designed to interrogate epigenetic al-
terations, particularly DNA CpG methylation, have been
developed. These arrays were initially designed based on
immunoprecipitation (MeDIP) or enzymatic digestion
followed by hybridization to a bacterial artificial chromo-
some or oligonucleotide CpG island array [14,15]. Subse-
quently, there has been a move towards arrays designed
on the premise of SNP detection arrays, and applied to
bisulfite converted DNA [16-18]. Probes are designed* Correspondence: a.feber@ucl.ac.uk
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reproduction in any medium, provided the orfor the detection of C/T alterations based on the conver-
sion of unmethylated cytosine with bisulfite. The relative
ratio of methylated (C) to unmethylated (T) residues is
then used to define the methylation state of a particular
locus [16].
The integration of genomic and epigenomic data from
the same sample is becoming increasingly popular as we
try to garner a greater understanding of the complex
mechanisms driving the development and progression of
cancers. Although at present arrays still prove the most
cost-effective method of assessing both copy number and
DNA methylation state, this interest in integrating multiple
data sets means a significant increase in costs associated
with these projects. Huge international efforts are currently
underway through the International Cancer Genome Con-
sortium (ICGC) and the Cancer Genome Atlas (TCGA)
projects to produce genomic and epigenomic data on a
huge number of human cancers. At present these data are
generated on separate array platforms, with over 6,200
SNP arrays and 6,300 methylation arrays used to date to
generate genomic and epigenomic profiles from the same
sample. This, therefore, not only doubles the cost but also
the amount of specimen used. The latter is particularly im-
portant when considering the potential effects of tumor
heterogeneity on disease development, where subtle areas
of a tumor are genetically and epigenetically different,
which may ultimately confer a different phenotypic trait,
such as differing metastatic potential [19].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Genomic probe distribution
Affymetrix SNP 6.0 Illumina CytoSNP Illumina 450 K methylation array
Number of probes 945,806 296,715 485,577
Median intermarker distance (kb) 2.3 6.1 0.35
Mean intermarker distance (kb) 3.0 10.8 5.8
Number of probes, mean and median intermarker distance interrogating copy number alterations from Affymetrix SNP 6.0, Illumina CytoSNP and Infinium
HumanMethylation450 BeadChip.
Feber et al. Genome Biology 2014, 15:R30 Page 2 of 13
http://genomebiology.com/2014/15/2/R30We therefore sought to assess if the Infinium Human-
Methylation450 BeadChips (the methylation array of choice
for the ICGC and TCGA) could be used to define regions
of CNA as well as sites of aberrant CpG methylation. It has
already been shown, for low density methylation arrays and
high resolution whole genome bisulfite sequencing, that
changes in genomic content do not impact on the ability of
these arrays to accurately define the methylation state for
individual loci and that these technologies also have poten-
tial utility in detecting CNAs [20-22]. As the Infinium
methylation arrays are, in essence, SNP arrays, providing
high density coverage of the genome, the question is do
they have the sensitivity and specificity to detect CNAs with
the same accuracy as existing technologies. This will not
only allow analysis and ultimately the integration of both
epigenetic and copy number from exactly the same DNA
specimen, potentially important when considering the ef-
fects of tumor heterogeneity on disease development and
progression [19,23], but will also significantly reduce the
cost of integrated epigenomic cancer studies looking to in-
corporate both data types.Results and discussion
Influence of copy number alteration on methylation state
Prior to evaluating whether the Infinium array could detect
CNAs, we first sought to assess whether alterations in gen-
omic content influenced the methylation state inferred by
the Infinium HumanMethylation450 BeadChips. Previous
analysis of similar low density Infinium type arrays
(GoldenGate) have shown that changes in DNA methyla-
tion are unaffected by copy number (CN) state [20].
Figure 1 shows the average beta value (methylation score)
for all potential sites on the Infinium array as a function
of CN determined from Affymetrix SNP6.0 or Illumina
CytoSNP arrays from 11 chondrosarcoma and 74 glio-
blastoma multiforme (GBM) tumors. It also shows the
average beta value for all potential sites on the Infinium
array as a function of CN determined from an Affymetrix
SNP6.0 array from 144 bladder cancer and 178 prostate
cancer samples, respectively.
These data show that CN has little impact on methy-
lation (Figure 1) in either series at regions of heterozy-
gous loss or single copy gains when compared with
regions of normal CN. However, there does appear to
be an association when assessing homozygous deletionand amplification (P < 2.2e-16), where a significant
negative correlation is observed with both data sets.
An association with beta value and homozygous loss
was as expected as low/no signal does not allow accurate
assessment of methylation; in fact, most probes in these
regions fail to pass the Illumina signal quality detection
P-value (defined by the comparison of signal from the
target compared to that of negative controls (Illumina
user manual)), and are removed in standard methylation
analyses. Unexpectedly, however, a significant negative
correlation was observed between regions of SNP array
amplification and reduced beta values in all data sets.
Unlike in regions of deletion, over 97% of probes in
regions of amplification pass the detection P-value. On
closer inspection, this negative correlation appears to
be driven by the Infinium probe distribution. A higher
proportion of probes in regions of focal amplification
are located in CpG islands, which are predominately
unmethylated, when compared with regions of normal
ploidy [12,13,24]. Separating the Infinium probes within
regions of amplification into CpG island-associated ver-
sus non-CpG island-associated confirmed this (Figure S1
in Additional file 1), with CpG island-associated probes
having a mean beta of 0.28 compared with 0.62 for non-
CpG island-associated probes (similar beta values are
observed if regions of no change and gain are partitioned
in a similar fashion). The inherent complex dynamics
between CN and methylation means it is difficult to dis-
entangle biology from systematic biases.
Array artifact removal
Furthermore, as with other array-based platforms, tech-
nical artifacts, such as batch effects and genomic wave,
may impinge on the accurate profiling of CNA form the
Infinium arrays. A ‘genomic-wave’ artifact, a probe effect
that correlates with surrounding genomic GC content
and is commonly observed in other comparative gen-
omic hybridization and SNP array platforms, and is also
manifest on the Infinium arrays [25,26]. In order to help
negate any effects of local CG content in calling CNAs,
we performed a loess correction prior to CNA analysis,
which estimates and removes the wave effects [25].
In a similar fashion, batch effects have been shown to
have a substantial effect on high throughput array-based
platforms, and are particularly apparent with the Infinium
arrays, particularly when considering scale projects, such
Figure 1 Association of methylation state with copy number. Box plots showing the influence of changing genomic content on methylation
state (average beta value) inferred from SNP (CytoSNP and Affymetrix SNP6.0) and Infinium arrays, respectively, for (A) chondrosarcoma, (B)
glioblastoma multiforme, (C) bladder cancer and (D) prostate cancer.
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tributed to batch as opposed to biological influence, we
also incorporated batch effect removal with the ComBat
function [29]. Batch effect removal significantly improved
the correlation between replicate samples across differing
batches (Figure S2 in Additional file 1): uncorrected R2 =
0.77 compared to batch-corrected R2 = 0.97. The correl-
ation of replicate samples within a single array was R = 0.99,
suggesting array position does not unduly affect signal in-
tensity. All subsequent analysis where carried out on wave-
and batch-corrected data (Figure S2 in Additional file 1).
It is well documented that the different Infinium assay
designs (type I and type II) show considerable probe ef-
fects [16,30]. For example, when assessing methylation,
the beta values derived from Infinium II probes were less
accurate and reproducible than those obtained from Infi-
nium I probes [30]; it has therefore been suggested (at
least for methylation analysis) that the differing probe
types be treated independently. We initially took this ap-
proach when utilizing these arrays to assess CN, as the
intensities of the two probe types also show considerable
differences [16,30].Copy number alteration profiling using Infinium
methylation arrays
Our initial motivation was to assess if the Infinium
HumanMethylation450 BeadChips could provide infor-
mation on genomic rearrangements with a level of ac-
curacy comparable to current gold standard SNP arrays.
As the Infinium arrays are, in essence, SNP arrays, with
probes designed to interrogate the relative ratio of a
methylated to unmethylated (C to T) template in bisul-
fite converted DNA, and as the methylation state (beta
value) is defined by a relative ratio of methylated probe
signal intensity to the total signal intensity of both meth-
ylated and unmethylated probes, it is logical to expect
that these arrays may also allow assessment of CN. If
total (unmethylated plus methylated) probe intensity is
representative of CN, then the simplest of CN changes,
that is, differences in the sex chromosomes between
males and females, should be clearly detectable. Figure 2
shows the total signal intensities of the autosomal and
sex chromosomes for normal reference DNA and 11
chondrosarcoma patients. These data clearly show a sig-
nificant (P < 2.2e-16) difference between the autosomal
Figure 2 Changes in Infinium probe intensities between sex chromosomes. (A) Box plots of Infinium total signal intensities for autosomes
and sex chromosomes for male and female patients (autosome (green) and sex chromosomes (chromosome X (red), chromosome Y (blue)).
(B) Box plots of Infinium intensities for autosomes and sex chromosomes for 11 chondrosarcoma samples (females, red; males, blue).
Feber et al. Genome Biology 2014, 15:R30 Page 4 of 13
http://genomebiology.com/2014/15/2/R30chromosomes and sex chromosomes and that the Infi-
nium methylation arrays can potentially detect single
copy alterations.
We subsequently assessed the relationship between
Infinium probe intensity and differing CNA states de-
fined by SNP array from an in-house series of matched
Infinium and CytoSNP arrays along with 386 samples
from the TCGA project, representing three tumor types,
GBM, prostate cancer and bladder cancer. As expected,
regression coefficients confirmed that the mean Infinium
signal intensity increases monotonically with CNA state
(Figure 3), with a significant difference (P <0.0001) in
mean Infinium signal at all levels of CN states, except
for putative homo- and heterozygous loss in the GBM
samples, where no difference is observed (P = 0.76). It
should be noted that, for both sample cohorts, there
were sufficient Infinium probes within regions of poten-
tial homozygous/heterozygous loss (defined on the SNP
arrays (CytoSNP and SNP6.0)) to allow comparison, and
while in theory no signal should be detectable when no
copies exist (heterozygous loss), no two probes from the
Infinium or SNP arrays overlap the same genomic loci,
and that there is a stochastic component to both the as-
signment of CN and measurement of intensity that mayaccount for this lack of correlation in regions of hetero-
zygous/homozygous loss.
Finally, we sought to define CN profiles from Infinium
array data. CNAs were identified using circular binary
segmentation in the Bioconductor package DNAcopy
[31]. We initially analyzed both probe types independ-
ently and evaluated the concordance of CNAs identified.
Using the default parameters, type II probes appear to
show a higher degree of ‘noise’ than the type I probes.
Despite this, the concordance of CNAs called by both
probe types (when considering large regions) is high
(97%), although this is significantly lower when consider-
ing smaller focal alterations (24%). However, this may
also somewhat reflect the differing genomic densities of
the two probe types. Comparing overlapping regions
only showed the CNA states generated from the two
probe types to be highly correlated (R2 = 0.94, range
0.48 to 0.99; Figure S3 in Additional file 1), allowing the
two probe types to be coalesced.
To confirm that CNA analysis can detect single copy
events, we compared normal reference DNA from single
male and female subjects. Figure 4 shows example CNA
profiles of reference male versus female samples, between
which a significant difference in the CN state of the sex
Figure 3 Comparison of Infinium total probe intensity and changing copy number. Box plots showing the association of total probe
signal intensity from the Infinium arrays and copy number state inferred from SNP arrays for (A) chondrosarcoma, (B) glioblastoma multiforme,
(C) bladder cancer and (D) prostate cancer.
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ample of a highly aneuploid malignant genome. These
data indicate that the Infinium HumanMethylation450
BeadChips, when combined with circular binary segmen-
tation, can detect both single copy and potentially high
level CNAs.Figure 4 Normal and malignant copy number profiles. (A) CN profile f
aneuploid cancer genome (versus male reference) derived from the Infiniu
segmented CN is shown in red.Correlation between Infinium and SNP array-defined
CNAs
We next sought to assess whether the Infinium arrays
could give a robust definition of CNAs compared to the
gold standard SNP arrays for aneuploid malignant ge-
nomes. CNAs were determined from both SNP arrays asor normal female versus male reference. (B) CN profile for a highly
m arrays. Individual chromosomes are shown in green/black and
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GBM samples. For bladder cancer and prostate cancer
samples, processed CNA estimates were download dir-
ectly from the TCGA project.
We assessed the correlation of all 407 samples with
paired Infinium and SNP array CNA profiles. In the ma-
jority of cases, global CN profiles from the different plat-
forms appeared highly correlated with an average
correlation coefficient of 0.91, ranging from 0.29 to 0.99,
and show a similar frequency and amplitude of alter-
ations. Figure 5 shows CN profiles from a single sample
for chromosome 12 for both Illumina CytoSNP and Infi-
nium 450Methylation Bead arrays as well as an overlay
of these. It also shows the correlation between Infinium
CNA and SNP array CNA profiles for the whole genome
and for chromosome 12 (R2 = 0.96).
To assess the robustness of CNAs identified from the
Infinium arrays, we compared them with CN profiles
generated from a SNP array for matched samples. We
initially assessed the agreement of large rearrangements
(that is, alterations of >10 Mb) for both gains and losses.
This analysis showed that a total of over 94% of large
chromosomal gains and 97% of losses were identified by
both Infinium and the SNP array, suggesting that the
Infinium arrays show sufficient sensitivity to detect large
scale, predominately single copy alterations.
Copy number alteration detection sensitivity
Besides the detection of large chromosomal rearrange-
ments, we also sought to evaluate the ability of the Infinium
arrays to detect focal alterations, including small (<1 Mb)
high-level amplifications and homozygous deletions. WeFigure 5 Comparison of Infinium and SNP copy number profiles. CN p
(A) Infinium array, (B) CytoSNP and (C) combined Infinium and CytoSNP. (D
array CN states from matched samples. (E) Scatter plot of Infinium and SNPinitially assessed the overlap between all regions of focal
genomic alteration (<1 Mb) independent of alteration
threshold; these regions were termed candidate true posi-
tives. In total 76% of all focal regions of alterations are iden-
tified in common between the SNP and Infinium arrays. Of
those alterations showing a discrepancy between the Infi-
nium and SNP arrays, approximately 25% are identified by
the SNP array only (candidate false negative), while the
remaining approximately 75% are identified by the Infinium
array only (candidate false positive). The disparity in the call
rates between the array platforms could be attributed to the
differing array designs and the gene-centric nature of the
Infinium arrays. When the analysis is limited to regions
with sufficient probe coverage (minimum marker = 3) to
call alterations in both arrays, over 79% of common alter-
ations are detected. This resulted in an overall sensitivity of
0.71 and specificity of 0.83. To assess the performance of
the Infinium array to detect CNAs with the same accuracy
as SNP arrays, we plotted the binomial probability of an al-
teration being called a true positive versus alteration cover-
age at differing alteration thresholds (that is, gain, loss,
amplification and deletion) across all 407 paired SNP Infi-
nium array comparisons (Figure 6). This confirmed that
the Infinium arrays show a good level of accuracy in de-
tecting alterations at all levels of alteration across multiple
studies (Table 2).
Copy number alteration resolution
As highlighted above, Infinium arrays define a significant
number of CNAs that are not present in the SNP array
data (candidate false positives). We sought to determine
whether these alterations are entirely down to array designrofiles for chromosome 12 for a single chondrosarcoma sample using
) Scatter plot showing the correlation between Infinium CN and SNP
array CNA states for chromosome 12 only.
Figure 6 Coverage plots of candidate true positives to assess
the sensitivity and specificity of alterations defined by the
Infinium arrays. At each alteration threshold (deletion, blue; loss,
red; gain, black; amplification, green) we counted the alterations that
overlap between matched arrays. The number of overlapping
regions (candidate true positives). Dotted lines represent 95%
confidence intervals.
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of these false positives (92%) appear to be regions devoid
of sufficient probes to call a change on the SNP arrays.
For example, Figure 7 shows LOH (loss of hetrozygosity)
of the entire chromosome 9 by both SNP and Infinium ar-
rays, along with the focal, potential homozygous deletion
of a further four regions, including the loci encompassing
the tumor suppressor gene CDKN2A. Three of the four
homozygous deletions are identified by both array types,
apart from an approximately 10 kb region (Figure 7) not
detected by the CytoSNP array. This region (log2R = -2.7)
contains 24 probes on the Infinium arrays and appears to
span approximately 34 kb (first 3 exons) and 1.2 kb up-
stream of PTCH1 only (9 probes in the remaining 44 kb
of PTCH1 showed heterozygous loss only, log2R = -0.36,
similar to the remainder of Chr9). However, this region is
represented by only a single probe on the CytoSNP array
(nearest neighbors 5′ = 7.34 kb and 3′ = 6.99 kb).Table 2 Infinium sensitivity and specificity
Sensitivity
Deletion Loss Gain Amplification
Chondrosarcoma 0.83 0.91 0.89 0.69
GBM 0.97 0.85 0.87 0.75
Bladder cancer 0.62 0.81 0.79 0.67
Prostate cancer 0.6 0.81 0.85 0.63
The sensitivity and specificity of CNAs identified between SNP array and
Infinium methylation arrays for four tumor types across a range of
alteration types.Quantitative PCR validation confirmed the heterozygous
deletion of this region in PTCH1 (Figure S4 in Additional
file 1). Similarly, Figure 4 shows the homozygous deletion
of a small region centered on GSTT1; homozygous dele-
tion of this gene has been associated with increased sus-
ceptibility to many different cancer types, including
prostate cancer, renal cancers and osteosarcoma [32-35].
The Infinium data indicate this deletion spans approxi-
mately 12 kb and contains GSTT1 and a small proportion
of the neighboring LOC391322 only (Figure 8). This re-
gion also contains a single probe from the Affymetrix
SNP6.0 array and would be undetectable by the Illumina
CytoSNP arrays (Figure 8). Quantitative PCR validated the
homozygous deletion of GSTT1 (Figure S4 in Additional
file 1). Although we have not mapped the full extent of
these deletions, these data highlight the potential utility of
these arrays to identify novel small alterations that are not
detectable with existing SNP array platforms.
We further validated CNAs identified by the Infinium
arrays with the targeted exome-sequencing of key cancer
genes [36]. This analysis revealed greater than 90% con-
cordance between alterations identified by Infinium CNA
profiling and targeted exome sequencing (Figure S5 in
Additional file 1). Of overlapping loci, 45 alterations were
identified from Infinium CNA profiling with a false posi-
tive rate of 8%, and a similar false negative rate (8.8%)
[36], further highlighting that the Infinium arrays provide
a reliable, robust and cost-effective method of identifying
CNAs in human cancers.
Conclusion
There is increasing interest in the integration of genomic
and epigenomic data from the same DNA specimen in
order to provide greater insight into disease processes. It
is particularly intriguing to integrate genomic CN and
DNA methylation data, which may allow the identifica-
tion of synergistic mechanisms for the inactivation of
tumor suppressor genes or the activation of oncogenic
pathways [3]. However, the integration and ultimately
the interpretation of these integrated datasets are both
costly and challenging if carried out separately.
Here we sought to evaluate whether the Infinium
HumanMethylation450 BeadChip could be utilized to
determine CNAs as well as epigenetic alterations. Ini-
tially, we sought to confirm that the methylation state
inferred by the Infinium HumanMethylation450 Bead-
Chip was not biased by altered CN state. We show there
is little bias when comparing normal (two copies) to het-
erozygous loss (one copy) or single copy gain (three cop-
ies). However, there does appear to be a correlation at
loci of complete genomic loss, potential homozygous de-
letion (more than one copy) and amplification (more
than four copies). Association of methylation and CNA
state with homozygous loss is unsurprising and has little
Figure 7 Infinium unique PTCH1 deletion. CN profiles for chromosome 9 for a single chondrosarcoma sample generated from Infinium
HumanMethylation450 BeadChip (upper panel) and CytoSNP arrays (middle panel). The Infinium array-specific deletion of PTCH1 is highlighted
(blue box).The lower panel shows the genomic organization of the Infinium unique PTCH1 region of deletion and the distribution of probes on
the Infinium methylation, CytoSNP and SNP 6.0 arrays.
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generally removed from methylation analysis due to sig-
nal intensities indistinguishable from background (low
detection P-value). However, it may represent a con-
founding factor effect when comparing methylation in
samples with and without CNA. For example, a tumor
suppressor deleted in a proportion of samples may be
hypermethylated in others, but in many Infinium methy-
lation array analysis pipelines this information will be
lost due to the removal of missing data. This highlights
the importance of integrated analysis using both CNA
and methylation data. The strong negative association
between methylation state and regions of high level ampli-
fication was less anticipated, and appears to be a result of
the genomic distribution of probes as opposed to inherent
biases of the arrays. As most probes in regions of amplifi-
cation fall within CpG islands, which are predominately
unmethylated, these therefore contribute to the apparent
loss of methylation in regions of amplification.Our primary objective was to assess whether the Infi-
nium HumanMethylation450 BeadChip could be used to
accurately assess CNAs to the same degree of reliability
and sensitivity as standard SNP array platforms, such as
the Affymetrix 6.0 SNP or Illumina CytoSNP arrays. Spe-
cifically, we compared Infinium CNA profiles from sam-
ples with matched SNP array data. Using the same
algorithm for all array types, we show that approximately
85% of all alterations were identified in both SNP and Infi-
nium arrays (when regions contain sufficient overlapping
probes). Interestingly, we see a reduced concordance when
assessing smaller alterations, with a high number of false
positive alterations identified by the Infinium arrays com-
pared to SNP platforms. The majority of these appear to
be results of differences in array design and the gene-
centric design bias of the Infinium arrays. Unlike the
standard SNP array design, with probes roughly evenly
distributed throughout the genome, the Infinium arrays
are very much gene-centric in their design, with 95% of
Figure 8 Infinium unique GSTT1 deletion. CN profiles for a proportion of chromosome 22 for a single chondrosarcoma sample generated from
Infinium HumanMethylation450 BeadChip (upper panel) and CytoSNP arrays (middle panel). The Infinium array specific deletion of GSTT1 is
highlighted (blue box). The lower panel shows the genomic organization of the Infinium unique GSTT1 region of deletion and the distribution of
probes on the Infinium methylation, CytoSNP and SNP 6.0 arrays.
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average, >9 probes per gene. Therefore, although the Infi-
nium arrays may lack the resolution of SNP arrays to de-
tect alterations in large intergenic regions or gene desert
regions, they provide high resolution coverage of the ma-
jority of coding loci. This allows for the identification of
discreet alterations of individual genes, which would not
be detected by standard SNP arrays. Similarly, with over
94% of CpG islands represented, these arrays may also
allow the identification of small alterations within regula-
tory regions, potentially revealing novel mechanisms of
gene disregulation. Therefore, the gene-centric/biased de-
sign of the Infinium array has a greater potential to iden-
tify driver CNAs involved in tumorigenic processes.
Furthermore, as the same loci can be interrogated for
both methylation and CN in the same DNA sample, the
analysis potentially allows easier integration of epigenetic
and genomic data. The integration of methylation and CN
data can provide fascinating insights into the underlyingbiology of malignant processes where the challenge is to
identify driver from passenger alterations [3]. For instance,
a change in genomic content (that is, single copy gain or
loss) does not have to correlate with a linear change in
methylation; in fact, it is those genes that show an inverse
correlation between CNA and methylation that may be
most important. For example, tumor suppressor genes
that undergo a ‘double hit’ - that is, heterozygous loss and
hypermethylation - or oncogenes in a region of gain that
are hypomethylated compared with neighboring genes
may represent those genes most likely to be differentially
expressed and consequently drivers of tumorigenic pro-
cesses. Hence, through utilizing the Infinium arrays for
both epigenetic and CN analysis, it may be possible to
more accurately distinguish between genes that drive the
selection of a malignant phenotype from those that are
passengers within an amplified or deleted region.
Finally, it can be difficult to compare CNA data across
different high-density array platforms, particularly given
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data with differing algorithms can lead to varying results
[37-39]. Even given these caveats, these data show the util-
ity of using the Infinium HumanMethylation450 Bead-
Chips to define CNAs in human cancers. We show that
the Infinium Arrays are as robust and sensitive as current
high density SNP arrays for the detection of CNAs and
appear highly applicable for providing estimates of CN as
well as a measure of methylation state. Furthermore, we
highlight that the gene centric design of the arrays may be
beneficial, in allowing the identification of alterations con-
taining single genes or just regulatory regions, which may
aid in our understanding of the complex genomic and epi-
genomic interactions driving the development and pro-
gression of a malignant phenotype.
Materials and methods
Study population
DNA from 11 chondrosarcoma specimens were subjected to
profiling on Infinium HumanMethylation450 BeadChip and
HumanCytoSNP-12 BeadChip (GSE40853) [40]. The mater-
ial was obtained from the RNOH Musculoskeletal Biobank,
with approval provided by the Cambridgeshire 1 Research
Ethics Committee (reference number 09/H0304/78).
Infinium methylation data with matched targeted exome-
seq data were generated from 44 formalin-fixed paraffin
wax-embedded (FFPE) head and neck squamous cell car-
cinoma (HNSCC) samples [41] (GSE38271, SRP034519).
Ethical approval for these samples was granted by the UCL/
UCLH Ethics Committee (reference number 04/Q0505/59).
Finally, matched Infinium array and Affymetrix SNP6.0
array data were downloaded from TCGA DataPortal for
74 GBM samples [42] and for 178 prostate cancer samples
[43].
Genome-wide methylation profiling
For chondrosarcoma and HNSCC, 1 μg of DNA from fresh
frozen tissue and 2 μg from FFPE tissues [41] were bisulfite
converted using the EZ DNA Methylation kit (Zymo Re-
search Corp. Irvine, CA, USA) according to the manufac-
turer’s instructions, with the exception of FFPE samples,
which were bisulfite converted using a modified protocol
[44]. Bisulphite converted samples were processed and hy-
bridized to the Infinium HumanMethylation450 BeadChip
according to the manufacturer’s recommendations. Subse-
quent data were processed and beta values computed using
the methylation module of the GenomeStudio software
(version 1.9.0; Illumina). Briefly, each CpG locus interro-
gated is represented by signals corresponding to both the
methylated (M) and unmethylated (U) alleles, respectively.
The beta value represents the ratio of the intensity of the
methylated bead type to the combined locus intensity: β =
max(M, 0)/(max(M,0) +max(U,0) + 100) and reflects the
methylation status of a specific CpG site.CytoSNP
DNA (300 ng) from 11 chondrosarcoma specimens and
one normal reference DNA sample were processed and
hybridized to the HumanCytoSNP-12 BeadChip according
to the manufacturer’s instructions. Subsequent data were
processed and R values computed using the genotyping
module of the GenomeStudio software (version 1.9.0; Illu-
mina). Further analysis and identification of CNAs was
carried out in R (version 2.15.0) [45].
Identification of copy number alterations
CNA data were generated from un-normalized signal in-
tensities. Signal intensities were extracted for each sample
using GenomeStudio. Probe intensities were subsequently
subjected to GC content normalization, carried out using
cyclic loess and log2 ratios, generated to averaged normal
reference samples [25]. Circular binary segmentation,
from the R package DNAcopy, was then performed to de-
fine chromosomal segments with differing CN states, with
the following settings: alpha = 0.001, undo.splits = ‘sdundo’,
min.wdith = 3 [31]. Thresholds for the identification of
single copy CNAs were derived from the difference in log
ratio between normal reference DNA from male and
female samples (log2 ± 0.33), denoting a single copy
change in the X chromosome; high-level amplifications
and homozygous deletions were defined incrementally
from this threshold. The level of noise was determined
from the median deviance of neighboring probes. Probes
that show a high degree of variability, such as the highly
polymorphic major histocompatibility (MHC) region on
the short arm of chromosome 6, were removed from sub-
sequent analysis.
This method for identifying CNAs from the Infinium
methylation arrays is incorporated in the ChAMP Bio-
conductor package [46,47], an Infinium HumanMethyla-
tion450K array integrated analysis pipeline that allows
quality control, normalization, calling of differentially
methylated regions and methylation variable positions
along with detection of CNAs [47].
Copy number alterations from reference CytoSNP arrays
were generated with DNAcopy (chondrosarcomas) as
above from normalized R values. We analyzed publicly
available GBM Affymetrix SNP6.0 segmented data to iden-
tify CNAs. Thresholds derived from the difference between
sex chromosomes in male and female patients was used to
identify single CN gains and homozygous deletions. Ampli-
fications and homozygous deletions were assessed using in-
cremental thresholds.
Correlation between Infinium and SNP array-defined
CNAs
Regression analysis was used to determine the association
between signal intensities and CNAs from the Infinium
HumanMethylation450 BeadChip and CNA status defined
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This was carried out in R using Bioconductor packages glm
or gam. The Bioconductor packages and iRanges [48] were
used to define overlapping regions between Infinium and
SNP array CNA data from all 407 paired samples.
Binomial probabilities of true positive detection were
calculated across all 407 samples at any given CNA al-
teration threshold (deletion, loss, gain or amplification).
We define true positive binomial probabilities first by
defining true positive counts. The true positive count is
defined as the number of overlapping regions between
paired samples on any two platforms at any given alter-
ation threshold and alteration size. A binomial test was
used to convert true positive counts to binomial prob-
abilities with 95% confidence intervals for each sample
comparison.
Sensitivity was defined by the number of true positives
over the total number of alterations (true positives plus
false negatives) detected by the Infinium array at any
given alteration threshold. Specificity was determined by
the Infinium false positive call rate (that is, an Infinium
CNA identified in a region of no change defied by the
SNP array). True negatives were defined as overlapping
genomic regions without alteration on both platforms,
compared to the number of Infinium false positives plus
true negatives. Only windows with more than three
probes in both platforms were assessed.Targeted exome sequence analysis
Matched tumor and germline DNA from 44 FFPE
HNSCC samples were subjected to targeted exome cap-
ture and next-generation sequencing [36,41]. Briefly, ex-
ome sequencing was carried out using a custom
SureSelect capture kit, representing 3,230 exons in 182
cancer-related genes plus 37 introns from 14 genes often
rearranged in cancer. Paired-end sequencing was per-
formed using the HiSeq2000 (Illumina). Reads were subse-
quently mapped to the reference human genome (hg19)
using the BWA aligner and processed using SAMtools
[49], Picard [50] and the Genome Analysis Toolkit
(GATK) [51]. CNAs were detected by comparing targeted
genomic DNA sequence coverage with a process-matched
normal control sample. Genomic rearrangements were
detected by clustering chimeric reads mapping to targeted
introns [36,47].Quantitative PCR validation of alterations
Deletions of PTCH1 (chromosome 9) and GSTT1 (chromo-
some 22) were validated in triplicate biological replicates
using SYBR-Green quantitative PCR. Loss of these regions
was determined relative to the control gene ACTB
(chromosome 7), a universal housekeeping gene.Additional file
Additional file 1: Figures S1 to S5. Figure S1. Distribution of beta
values for promoter associated and non-associated CpGs. (A) Boxplot of
beta values for CpGs in non-CpG island associated promoters and CpG is-
land associated promoters for regions of genomic amplification. (B)
Regions of genomic deletion, (C) Regions of genomic loss, (D) CNA neutral
regions and (E) Regions of single copy gain.
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